Evolent Health Inc Class A Common Stock (EVH) fair value

ACCE thesis

Evolent Health sells care management technology and services to value-based payers and providers, most notably its specialty-care and oncology programs that manage high-cost spend for health plans. Its edge is a sticky, outcomes-linked model in which it takes on risk for defined populations, which has produced 46.9% revenue growth, though gross margin of 17.2% and an operating margin of -1.3% show how thin the economics remain. The near-term story is whether scale lets operating leverage arrive before the balance sheet is tested, since ROE of -67.0% reflects losses that have yet to close. At a forward P/E of 8.6 on a roughly $551M market cap, the stock prices in a turnaround that the company has not yet demonstrated, so the question for the team is whether margin progression in the next two reporting periods is visible enough to justify a deeper look at the debt and cash profile.